37results about "Cyclic peptides" patented technology

Disclosed is a peptide-immobilized bead library from which peptides are more likely to be obtained as candidates of useful substances such as pharmaceuticals, and with which the amino acid sequence bound to a target substance can be more easily analyzed, compared to known OPOB libraries. The peptide-immobilized bead library has a structure of General Formula [I]. In General Formula [I], X is an amino acid residue; n is an integer of 4 to 8; Y is a cyclization structure; A is a spacer structure; B is a specific cleavage site-containing structure; and the 4 to 8 amino acid residues of X are each independently randomly selected.

The invention discloses a peptide with an anti-photoaging effect as well as a preparation method and application of the peptide. The cyclic dipeptide cyclo (LO) and the linear dipeptide LO disclosed by the invention can be used for remarkably inhibiting the activity of MMP-1 and efficiently blocking collagen degradation. In addition, the cyclic dipeptide and the linear dipeptide have no cytotoxic effect when being co-cultured with fibroblasts, so that the cyclic dipeptide and the linear dipeptide have no stimulation and side effects on cells, and are high in safety and good in stability. The cyclic dipeptide and the linear dipeptide disclosed by the invention can resist UVA (Ultraviolet A) damage, have a promoting effect on cell proliferation activity after UVA irradiation and have an anti-aging effect on cells after UVA irradiation. The two peptides disclosed by the invention can be used for preparing medicines or cosmetics for resisting light aging, resisting aging, beautifying and protecting skin. The peptide fragment disclosed by the invention has a good application prospect in the fields of medicines, cosmetics and the like.

To provide a new molecular modality capable of modulating the function of an undruggable target.SOLUTION: A compound (e.g., a macrocyclic compound comprising 14 to 40 ring atoms as shown below) capable of modulating a biological process by binding to presenter proteins (e.g., members of the FKBP family, members of the cyclophilin family, or PIN1) and target proteins (e.g., eukaryotic target proteins such as mammalian target proteins or fungal target proteins or prokaryotic target proteins such as bacterial target proteins).SELECTED DRAWING: None

A bicyclic peptide composition and its application are disclosed, relating to the field of peptide technology. The cyclic peptide composition comprises component X and component Y, wherein component X is cyclic octapeptide-69, and component Y is selected from one or more of the following cyclic peptides: Cyclo-(Pro-Lys-Glu-Lys) and Cyclo-(Val-Leu-Gln-Trp-Val-Lys). Specifically, the cyclic peptide composition and its use in the preparation of cosmetics are disclosed.

Described herein is the monohydrochloride salt and the free zwitterion of the macrocyclic peptide antibiotic 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid. Also described are amorphous and crystalline forms of the hydrochloride salt and the free zwitterion, as well as methods of making them and using them in medical therapy.

Disclosed are methods of producing conditionally active proteins that target senescent cells and are conditionally active in the extracellular environment of senescent cells. The methods include methods of using an evolved protein library and testing using physiological concentrations of bodily fluid components. Also disclosed are conditionally active proteins, antibodies, and antibody fragments for killing or removing senescent cells, conjugates and pharmaceutical compositions using these conditionally active proteins, and methods of treating age-related diseases, conditions, or disorders using the pharmaceutical compositions. Conditionally active proteins can be further evolved, conjugated to other molecules, masked, and reduced in activity by linking cleavable moieties.

Disclosed are a bicyclic peptide composition and application thereof, and relate to the technical field of polypeptides, the ring peptide composition comprising component X and component Y, the component X being a ring hexapeptide-8, and the component Y being selected from one or more of the following ring peptides: a ring octapeptide-69, Cyclo-(Pro-Lys-Glu-Lys), Cyclo-(Val-Leu-Gln-Trp-Val-Lys). Specifically, the ring peptide composition and the use thereof in the preparation of cosmetics are disclosed.

Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.

The invention discloses a sponge cyclic peptide compound and cyclic dipeptide, which comprise two amino acid fragments, namely proline and methionine sulfoxide, and provides application of the sponge cyclic peptide compound in an anti-Parkinson medicine, and the sponge cyclic peptide compound can obviously improve the movement speed of lesion zebrafish. Compared with the prior art, the invention has the advantages that a new compound is provided for developing and researching an anti-Parkinson medicine, and separation, synthesis and application of the active sponge cyclic peptide compound are provided.

This provides a novel, highly specific molecular probe for tumor diagnosis. [Solution] A compound having the structure shown in the following formula (A) is provided. Its use in the preparation of radionuclide labeling or radionuclide labeling reagents is further provided. Furthermore, a radionuclide preparation comprising the compound shown in formula (A) is provided. TIFF2026102884000026.tif67170

Embodiments of the disclosure include methods and compositions related to use of compound comprising a particular peptide linked to a dye. In specific embodiments, the peptide DIRG is linked to the BODIPY dye. In specific embodiments, the compositions are utilized for treatment of neurological conditions and secondary pathologies related therewith, such as spinal cord injury and Alzheimer's Disease, as examples.

The invention discloses a tetrapeptide-7 cyclic peptide as well as a composition and application thereof, and relates to the technical field of polypeptides, and the cyclic peptide has the following structure: Cyclo-[Gly-Gln-Pro-Arg]. In particular, the invention relates to the cyclic peptide or the salt thereof, or a composition of the cyclic peptide and the salt thereof, and application of the cyclic peptide and the salt in preparation of a composition for caring skin or mucosa.

Methods of generating conditionally active proteins that target senescent cells and which are conditionally active in an extracellular environment of a senescent cell. The methods include methods using libraries of evolved proteins and assays employing physiological concentrations of components of bodily fluids. Also disclosed are conditionally active proteins for killing or removing senescent cells, antibodies and antibody fragments, conjugates and pharmaceutical compositions employing these conditionally active proteins and methods for treatment of age-related diseases, conditions or disorders using same. The conditionally active proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety.

The present invention relates to a novel peptide derivative, which is a partially modified adiponectin receptor peptide and has higher stability and superior p-AMPK activity than existing adiponectin receptor peptides, and has the advantage of being advantageous for drug formulation due to improved physical properties and activity. Therefore, the peptide derivative of the present invention can be used for preventing or treating skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, and for preventing or improving aging, sensitive skin, wrinkles, or moisture.

This invention belongs to the field of genetic engineering technology, specifically relating to the construction and preparation of an NRPS gene, a vector, and a recombinant strain that produces high-yield cyclic dipeptides. This invention identifies an NRPS core gene from the sea squirt-derived fungus Diaporthesp. SYSU-MS4722, and uses this gene with Aspergillus oryzae as a heterologous expression host to construct a recombinant strain. The cyclic dipeptide natural product cyclo(Phe-Ala) was successfully isolated, with a yield reaching 110 mg / L, which is 20 times higher than the reported yield of cyclo(Phe-Ala) from the marine bacterium Pseudomonas putida. Therefore, the Aspergillus oryzae recombinant strain of this invention can be used for the efficient preparation of the cyclic dipeptide compound cyclo(Phe-Ala), and has significant application value.

The present invention relates to Muramyl dipeptide compounds having adjuvant activity. The present invention also discloses the process for the preparation of Muramyl dipeptide compound and their intermediates. The immuno-modulating properties of the Muramyl dipeptide compound and their use as NOD2 agonistic adjuvants in vaccine formulations is also disclosed.

To provide peptide compositions and methods for inhibiting neovascularization or development of pathogenic or aberrant blood vessels in human or other animal subjects.SOLUTION: Provided herein is a composition comprising a peptide consisting of an amino acid sequence of Gly-Arg-Gly-Cys-Thr-Pro. The composition is administered to a human or animal subject for inhibiting neovascularization or development of pathogenic or aberrant blood vessel in a therapeutically effective amount. The composition is also administered to the eye of a subject with neovascularization or development of pathogenic or aberrant blood vessels to treat the eye disease or disorder of the subject.SELECTED DRAWING: Figure 5

The invention discloses a method for preparing an on-DNA macrocyclic compound through a light-mediated on-DNA intramolecular desulfurization coupling reaction. According to the reaction, terminal alkene and sulfydryl in the on-DNA substrate are subjected to intramolecular desulfurization coupling reaction to form a macrocyclic structure under the conditions of blue light irradiation and existence of a photocatalyst and a desulfurization reagent. The method is easy and convenient to operate, the substrate is high in universality, low in cost and easy to obtain, a new method is provided for constructing the on-DNA macrocyclic compound, and the diversity of DNA coding macrocyclic library structures and conformations is enriched.

The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and / or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine proteases (e.g. Cathepsin B). The present invention also relates to various methods of using the inhibitor compounds to treat or prevent viral infections, including those caused by coronaviruses and influenza, conditions associated with KLK5, various malignancies, pre-malignant conditions, and cancer.

The invention belongs to the technical field of biomedical cosmetics, and discloses a double-target 5alpha-reductase and adiponectin receptor cyclic peptide as well as application and a preparation method thereof. The cyclic peptide is formed by cyclizing three amino acid units, namely arginine, phenylalanine and tyrosine through peptide bonds, and comprises pharmaceutically acceptable salts, solvates, stereoisomers or isotope labels of the cyclic peptide. The compound reduces generation of dihydrotestosterone by inhibiting 5alpha-reductase, activates an adiponectin receptor AdipoR pathway to promote energy metabolism and proliferation of hair papilla cells, and realizes double-target synergistic anti-alopecia. The invention also discloses application of the cyclopeptide in preparation of medicines or cosmetics for preventing or treating alopecia and a solid-phase synthesis preparation method. Through double-target synergistic interaction, the hair follicle cell proliferation rate can be remarkably increased at extremely low concentration, and the dosage is reduced compared with that of a traditional medicine; the composition is constructed by adopting physiological amino acid, has no systemic sex hormone side effect during local external use, and is high in safety.

The present disclosure provides a cyclic peptide derivative, a method for producing the same, and a composition. The present disclosure relates to a compound for modulating nervous system cell activity. More specifically, the compound of the present disclosure is capable of modulating the proliferation activity of astrocytes. The compound of the present disclosure has the effect of enhancing the proliferation activity of astrocytes. The features provided by the present disclosure can be used for a cyclic peptide derivative for modulating nervous system cell activity and a method for producing said cyclic peptide derivative.

The invention relates to a cyclic peptide compound and an application thereof, and provides a cyclic peptide compound which is shown in a formula I, is novel in structure and has the effect equivalent to or even better than that of GHK tripeptide, and an application of the cyclic peptide compound in a dermatological or cosmetic composition for stimulating hair growth or resisting skin aging. And the formula I is * AA1-AA2-GLY-HIS-LYS-AA4-AA3 *, and the formula I is shown in the description.

The present invention provides linkers, coupling drugs using them, antibody-drug conjugates, and their applications. Specifically, it provides a conjugate as shown in formula (II), or its stereoisomer, or a pharmaceutically acceptable salt thereof, where L is a linker (-GGFL-) as shown in formula (I). A conjugate having a linker as shown in formula (I) has high stability at non-target sites and can be rapidly activated at target sites. Formula (II): R1-L-R2

The present disclosure relates to cyclic oligopeptides that bind to interleukin-13 (IL-13), which are therapeutically useful in methods of treating or preventing IL-13-related skin disorders or conditions. The present disclosure also provides methods of treating or preventing an IL-13-related skin disorder or condition with an IL-13-binding cyclic oligopeptide. The present disclosure further provides methods of generating an IL-13-binding cyclic oligopeptide. The present disclosure provides cyclic oligopeptides that bind to IL-13, and methods of using such cyclic oligopeptides to treat IL-13-related skin disorders or conditions.

To provide methods of generating conditionally active senolytic antibodies that target senescent cells and that are conditionally active in an extracellular environment of a senescent cell.SOLUTION: Provided is a method comprising: evolving a DNA encoding a parent antibody or antibody fragment that binds to a target associated with a senescent cell to create a mutant DNA; expressing the mutant DNA to obtain a mutant antibody or antibody fragment; subjecting the mutant antibody or antibody fragment to an assay for a binding activity to the target under an extracellular condition of the senescent cell and to an assay for a binding activity to the target under a normal physiological condition; and selecting a conditionally active senolytic antibody or antibody fragment, the ratio of the activity of the conditionally active senolytic antibody or antibody fragment in the assay under extracellular conditions to the activity in the assay under normal physiological conditions being at least 1.3:1.SELECTED DRAWING: Figure 18B

The present invention provides a pharmaceutical composition containing a cyclic tetrapeptide that is useful for treating diseases. [Solution] A pharmaceutical composition for the treatment of a disease is provided, comprising a compound of formula (1). TIFF2026048697000028.tif6172 Cyclic tetrapeptides are particularly useful for coordinating to metals selected from Pb, Cd, Hg, and As.

The present disclosure provides a cyclic peptide derivative composition for treating or preventing central nervous system injured diseases.The present disclosure relates to a composition comprising a compound for treating or preventing a central nervous system injured disease or a pharmaceutically acceptable salt, solvate or prodrug thereof. More specifically, the composition of the present disclosure can treat or prevent atherosclerotic cerebral infarction, cardiogenic cerebral infarction or lacunar infarction. The technology provided by the present disclosure can be used for a cyclic peptide derivative for modulating nervous system cell activity and a method for producing said cyclic peptide derivative.

Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.